[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

JPS57149217A - Slow-releasing pharmaceutical preparation - Google Patents

Slow-releasing pharmaceutical preparation

Info

Publication number
JPS57149217A
JPS57149217A JP3376181A JP3376181A JPS57149217A JP S57149217 A JPS57149217 A JP S57149217A JP 3376181 A JP3376181 A JP 3376181A JP 3376181 A JP3376181 A JP 3376181A JP S57149217 A JPS57149217 A JP S57149217A
Authority
JP
Japan
Prior art keywords
water
drug
pharmaceutical preparation
slow
carrageenan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP3376181A
Other languages
Japanese (ja)
Inventor
Takashi Ogino
Kenji Kono
Yoshitsugu Yamada
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kaken Pharmaceutical Co Ltd
Original Assignee
Kaken Pharmaceutical Co Ltd
Kaken Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kaken Pharmaceutical Co Ltd, Kaken Chemical Co Ltd filed Critical Kaken Pharmaceutical Co Ltd
Priority to JP3376181A priority Critical patent/JPS57149217A/en
Publication of JPS57149217A publication Critical patent/JPS57149217A/en
Pending legal-status Critical Current

Links

Landscapes

  • Medicinal Preparation (AREA)

Abstract

PURPOSE: To provide a pharmaceutical preparation having improved slow-releasing property, by using a water-soluble polymer and carrageenan in addition to the main drug component.
CONSTITUTION: The slow-releasing pharmaceutical preparation is prepared by compounding a main drug component with a water-soluble polymer such as hydroxypropyl methyl cellulose and carrageenan preferably gelatinizable with water. The amounts of the polymer and the carrageenan are preferably 5W 40wt% and 10W70wt%, respectively, and the effective life of the drug action can be controlled by adjusting the contents of both additives. When the life of the drug action is enlogated, the number of the administration times can be reduced. Since there is no remarkable increase of the drug concentration in blood, the side effects can be lowered. Even a hardly water-soluble drug can be absrobed in high efficiency, since th pharmaceutical preparation dissolves in the digestive tracts. Accordingly, the present preparation is especially suitable for a hardly water-soluble drug having a water solubility of ≤1g/100ml.
COPYRIGHT: (C)1982,JPO&Japio
JP3376181A 1981-03-11 1981-03-11 Slow-releasing pharmaceutical preparation Pending JPS57149217A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP3376181A JPS57149217A (en) 1981-03-11 1981-03-11 Slow-releasing pharmaceutical preparation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP3376181A JPS57149217A (en) 1981-03-11 1981-03-11 Slow-releasing pharmaceutical preparation

Publications (1)

Publication Number Publication Date
JPS57149217A true JPS57149217A (en) 1982-09-14

Family

ID=12395409

Family Applications (1)

Application Number Title Priority Date Filing Date
JP3376181A Pending JPS57149217A (en) 1981-03-11 1981-03-11 Slow-releasing pharmaceutical preparation

Country Status (1)

Country Link
JP (1) JPS57149217A (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60174729A (en) * 1984-02-21 1985-09-09 Nippon Shinyaku Co Ltd Anticancer pharmaceutical composition
JPS61109710A (en) * 1984-11-05 1986-05-28 Taisho Pharmaceut Co Ltd Suppository for hemorrhoids
JPS61130239A (en) * 1984-11-30 1986-06-18 Dai Ichi Seiyaku Co Ltd Complex
WO2003000293A1 (en) * 2001-06-21 2003-01-03 Astrazeneca Ab Pharmaceutical formulation
US7202236B2 (en) 2002-05-31 2007-04-10 Astrazeneca Ab Modified release pharmaceutical formulation
US7273858B2 (en) 2002-05-31 2007-09-25 Astrazeneca Ab Salts
US7645751B2 (en) 2000-12-01 2010-01-12 Astrazeneca Mandelic acid derivatives and their use as thrombin inhibitors
US7781424B2 (en) 2003-05-27 2010-08-24 Astrazeneca Ab Modified release pharmaceutical formulation
US7820645B2 (en) 2006-12-06 2010-10-26 Astrazeneca Ab Crystalline forms
JP2018530537A (en) * 2015-09-14 2018-10-18 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Tablet with active ingredient release independent of medium

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55122726A (en) * 1979-03-16 1980-09-20 Asahi Chem Ind Co Ltd Prolonged release drug composition

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55122726A (en) * 1979-03-16 1980-09-20 Asahi Chem Ind Co Ltd Prolonged release drug composition

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60174729A (en) * 1984-02-21 1985-09-09 Nippon Shinyaku Co Ltd Anticancer pharmaceutical composition
JPS61109710A (en) * 1984-11-05 1986-05-28 Taisho Pharmaceut Co Ltd Suppository for hemorrhoids
JPS61130239A (en) * 1984-11-30 1986-06-18 Dai Ichi Seiyaku Co Ltd Complex
US7645751B2 (en) 2000-12-01 2010-01-12 Astrazeneca Mandelic acid derivatives and their use as thrombin inhibitors
US7803954B2 (en) 2000-12-01 2010-09-28 Astrazeneca Ab Mandelic acid derivatives and their use as thrombin inhibitors
WO2003000293A1 (en) * 2001-06-21 2003-01-03 Astrazeneca Ab Pharmaceutical formulation
US7700582B2 (en) 2001-06-21 2010-04-20 Astrazeneca Ab Pharmaceutical formulation
US7273858B2 (en) 2002-05-31 2007-09-25 Astrazeneca Ab Salts
US7763597B2 (en) 2002-05-31 2010-07-27 Astrazeneca Ab Salts
US7202236B2 (en) 2002-05-31 2007-04-10 Astrazeneca Ab Modified release pharmaceutical formulation
US7781424B2 (en) 2003-05-27 2010-08-24 Astrazeneca Ab Modified release pharmaceutical formulation
US7820645B2 (en) 2006-12-06 2010-10-26 Astrazeneca Ab Crystalline forms
JP2018530537A (en) * 2015-09-14 2018-10-18 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Tablet with active ingredient release independent of medium

Similar Documents

Publication Publication Date Title
BG42000A3 (en) Method for preparing suspension of microcapsulated bacampicilline salt of acid incorporation
KR890001598A (en) Dosing device with dosing member for administering beneficial agent
ES8106654A1 (en) Pharmaceutical composition containing Sanguinaria and Galangal suitable for treatment of periodentitis and tumours.
FI870588A0 (en) A process for preparing a sustained release solid dosage form
JPS57149217A (en) Slow-releasing pharmaceutical preparation
IL140848A0 (en) Treatment regimen for administration of phenylacetylacetylglutamine, phenylacetylisoglutamine and/or phenylacetate
FI962056A0 (en) Novel pharmaceutical composition for the preparation of a stable powder containing an active ingredient comprising a combination of acetylsalicylic acid and metoclopramide
DE59106162D1 (en) KAWA-KAWA EXTRACT, METHOD FOR PRODUCING IT AND ITS USE.
JPS57109721A (en) Carcinostatic agent
JPS57167919A (en) Preventing agent for intraperitoneal adhesion
JPS57200361A (en) "indomethacin(r)" pharmaceutical with low irritant action
JPS5661311A (en) Thial amide or prolonged pharmaceutical preparation comprising its salt
ATE1442T1 (en) PHARMACEUTICAL COMPOSITION CONTAINING ALL-E- OR 13-Z-7,8-DEHYDRO-RETINOIC ACID AND PROCESS FOR ITS PREPARATION.
JPS55122715A (en) Antidiabetic agent
US3487150A (en) Dextran sulphate treatment of peptic ulcers
JPS57158719A (en) Rectal administration pharmaceutical
JPS5612309A (en) Oral drug containing ubidecarenone
Kahn Effect of chlorothiazide on electrolyte excretion in intact and adrenalectomized rats
JPS5531028A (en) Injection
JPS5639019A (en) Antiviral agent
US4742082A (en) Solution of luprostiol and 1,2,-propanediol and methods of preparation and use
JPS5341418A (en) Preparation of antibiotic preparations of aminoglycoside series suitable for rectal administration
JPS5498339A (en) Carcinostatic agent
JPS5569510A (en) Carcinostatic agent
JPS5746919A (en) Remedy for radioinflammation and cushing's ulcer